Lannett plummets on JSP arrangement end

Lannett’s share price crashed by three-fifths in the wake of news that long-time partner and “primary finished-goods inventory supplier” Jerome Stevens Pharmaceuticals (JSP) would not be renewing the firms’ exclusive distribution agreement for levothyroxine sodium tablets, one of the company’s key products, among others.